Somatic coding mutations in human induced pluripotent stem cells (scientific article (publication date: 3 March 2011))

cites work (P2860)

Q38844338	10th anniversary of iPS cells: the challenges that lie ahead
Q26746033	A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects
Q31095888	A Method for Checking Genomic Integrity in Cultured Cell Lines from SNP Genotyping Data
Q38912649	A Novel Selectable Islet 1 Positive Progenitor Cell Reprogrammed to Expandable and Functional Smooth Muscle Cells.
Q46026523	A ZFN/piggyBac step closer to autologous liver cell therapy.
Q82693891	A better source of therapeutic stem cells
Q35369524	A bibliometric analysis of publications on pluripotent stem cell research
Q36144136	A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells
Q35087542	A comparison of non-integrating reprogramming methods
Q38551127	A dangerous method? The use of induced pluripotent stem cells as a model for schizophrenia.
Q37929077	A guide to stem cell identification: progress and challenges in system-wide predictive testing with complex biomarkers.
Q36165855	A highly efficient method for generation of therapeutic quality human pluripotent stem cells by using naive induced pluripotent stem cells nucleus for nuclear transfer
Q33949177	A human pluripotent stem cell surface N-glycoproteome resource reveals markers, extracellular epitopes, and drug targets.
Q39394802	A human stem cell model of early Alzheimer's disease pathology in Down syndrome
Q39096273	A mitochondrial strategy for safeguarding the reprogrammed genome
Q34236699	A model of cancer stem cells derived from mouse induced pluripotent stem cells
Q54346204	A novel coding method for gene mutation correction during protein translation process.
Q38880823	A novel human model of the neurodegenerative disease GM1 gangliosidosis using induced pluripotent stem cells demonstrates inflammasome activation
Q40148921	A novel method to quantify base substitution mutations at the 10-6 per bp level in DNA samples.
Q40203046	A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs
Q38236662	A practical guide to induced pluripotent stem cell research using patient samples
Q100386510	A promising iPS-based single-cell cloning strategy revealing signatures of somatic mutations in heterogeneous normal cells
Q27133763	A public resource facilitating clinical use of genomes
Q28072303	A review of Rett syndrome (RTT) with induced pluripotent stem cells
Q28078326	A review of induced pluripotent stem cell, direct conversion by trans-differentiation, direct reprogramming and oligodendrocyte differentiation
Q38004911	A review of the role of stem cells in the development and treatment of glioma.
Q38473359	A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation
Q35058629	A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells
Q38766241	A systematic review: differentiation of stem cells into functional pericytes
Q34037321	AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes.
Q61799087	Aberrant hiPSCs-Derived from Human Keratinocytes Differentiates into 3D Retinal Organoids that Acquire Mature Photoreceptors
Q36981270	Abnormalities in human pluripotent cells due to reprogramming mechanisms
Q38767506	Achilles' heel of pluripotent stem cells: genetic, genomic and epigenetic variations during prolonged culture
Q50085968	Acquired Genetic and Epigenetic Variation in Human Pluripotent Stem Cells
Q56765662	Activity of Retrotransposons in Stem Cells and Differentiated Cells
Q38129192	Adult-derived pluripotent stem cells
Q89259986	Advanced in vitro models of vascular biology: Human induced pluripotent stem cells and organ-on-chip technology
Q37988004	Advances and applications of induced pluripotent stem cells
Q38146404	Advances in cellular reprogramming: moving toward a reprieve from immunogenicity
Q35635245	Advances in reprogramming-based study of neurologic disorders
Q26782706	Advances in therapeutic CRISPR/Cas9 genome editing
Q35653333	Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells
Q36518127	Aging and reprogramming: a two-way street
Q38037460	Aging in the mouse and perspectives of rejuvenation through induced pluripotent stem cells (iPSCs).
Q38865190	Airway tissue engineering for congenital laryngotracheal disease
Q33849275	Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells
Q36283888	Alzheimer's disease in a dish: promises and challenges of human stem cell models
Q26750573	Amniotic Fluid Stem Cells: A Novel Source for Modeling of Human Genetic Diseases
Q57153004	Amniotic fluid stem cell models: A tool for filling the gaps in knowledge for human genetic diseases
Q37074405	Amniotic fluid stem cell-based models to study the effects of gene mutations and toxicants on male germ cell formation
Q38041896	Amniotic fluid stem cells to study mTOR signaling in differentiation
Q34044130	An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells
Q36747204	An Optimized Approach to Recover Secreted Proteins from Fibroblast Conditioned-Media for Secretomic Analysis
Q110697192	An Overview on Promising Somatic Cell Sources Utilized for the Efficient Generation of Induced Pluripotent Stem Cells
Q38913129	An atypical human induced pluripotent stem cell line with a complex, stable, and balanced genomic rearrangement including a large de novo 1q uniparental disomy.
Q34314350	An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells
Q59350176	An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells
Q37993981	An updated view on stem cell differentiation into smooth muscle cells
Q37360925	Analysis of induced pluripotent stem cells from a BRCA1 mutant family
Q37376120	Analysis of protein-coding mutations in hiPSCs and their possible role during somatic cell reprogramming
Q37900302	Aneuploid human embryonic stem cells: origins and potential for modeling chromosomal disorders
Q35202814	Aneuploidy is permissive for hepatocyte-like cell differentiation from human induced pluripotent stem cells
Q37564286	Antioxidant supplementation reduces genomic aberrations in human induced pluripotent stem cells.
Q58692112	Apoptosis: Reprogramming and the Fate of Mature Cells
Q42862289	Application of Stem Cell Technology in Dental Regenerative Medicine
Q34031951	Application of epigenome-modifying small molecules in induced pluripotent stem cells
Q38210765	Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases
Q57048119	Application of induced pluripotent stem cell transplants: Autologous or allogeneic?
Q90380343	Applications for Induced Pluripotent Stem Cells in Disease Modelling and Drug Development for Heart Diseases
Q43070454	Are embryonic stem and induced pluripotent stem cells the same or different? Implications for their potential therapeutic use.
Q47555708	Are there multiple cells of origin of Merkel cell carcinoma?
Q36673714	Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells
Q37882177	Assessing the safety of stem cell therapeutics
Q35878857	Assessment of the Tumorigenic Potential of Spontaneously Immortalized and hTERT-Immortalized Cultured Dental Pulp Stem Cells
Q33813801	Ataxia telangiectasia derived iPS cells show preserved x-ray sensitivity and decreased chromosomal instability
Q38007739	B cell maintenance and function in aging
Q35947171	Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells
Q38685965	Behavior of Xeno-Transplanted Undifferentiated Human Induced Pluripotent Stem Cells Is Impacted by Microenvironment Without Evidence of Tumors.
Q49334387	Bioengineered humanized livers as better three-dimensional drug testing model system
Q38978163	Bone regeneration using mesenchymal stem cells: challenges and future perspectives in regenerative surgery
Q39118764	Brain imaging genetics in ADHD and beyond - Mapping pathways from gene to disorder at different levels of complexity.
Q38739430	Bringing Neural Cell Therapies to the Clinic: Past and Future Strategies
Q46503312	Building stem-cell genomics in California and beyond
Q50960936	CGRP-alpha application: a potential treatment to improve osseoperception of endosseous dental implants.
Q41125370	CMD kinetics and regenerative medicine
Q91480411	CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease
Q52431028	CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.
Q27002443	Calcium signalling of human pluripotent stem cell-derived cardiomyocytes
Q39029362	Can cord blood banks transform into induced pluripotent stem cell banks?
Q90205011	Cancer-Related Mutations Identified in Primed and Naive Human Pluripotent Stem Cells
Q37922212	Capturing Alzheimer's disease genomes with induced pluripotent stem cells: prospects and challenges
Q35144550	Cardiac cell therapy: where we've been, where we are, and where we should be headed
Q38164335	Cardiac regeneration: current therapies-future concepts
Q38041270	Cardiac repair and restoration using human embryonic stem cells
Q38040206	Cardiac stem cell therapy: stemness or commitment?
Q42731596	Cell fate conversion by mRNA
Q27011667	Cell replacement strategies aimed at reconstitution of the β-cell compartment in type 1 diabetes
Q34267315	Cell replacement therapies: is it time to reprogram?
Q37992352	Cell therapy: promise fulfilled?
Q104481334	Cell-Based Therapy Manufacturing in Stirred Suspension Bioreactor: Thoughts for cGMP Compliance
Q47885870	Cell-based therapeutic strategies for multiple sclerosis
Q37987054	Cell-replacement therapy and neural repair in the retina
Q37610499	Cells derived from iPSC can be immunogenic - yes or no?
Q88946852	Cellular Models: HD Patient-Derived Pluripotent Stem Cells
Q37983703	Cellular genomics for complex traits
Q85074132	Cellular origin of testis-derived pluripotent stem cells: a case for very small embryonic-like stem cells
Q38062512	Cellular reprogramming and cancer development
Q38141509	Cellular reprogramming of human peripheral blood cells
Q38043833	Cellular reprogramming to reset epigenetic signatures
Q26829509	Cellular reprogramming: a small molecule perspective
Q26828934	Cellular reprogramming: recent advances in modeling neurological diseases
Q38344424	Cellular therapies based on stem cells and their insulin-producing surrogates: a 2015 reality check
Q35648164	Cellular therapy and induced neuronal replacement for Huntington's disease.
Q41013661	Challenges for the Therapeutic use of Pluripotent Stem Derived Cells
Q39075964	Changeability of the fully methylated status of the 15q11.2 region in induced pluripotent stem cells derived from a patient with Prader-Willi syndrome
Q38063646	Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy
Q38270797	Characterization of human neural differentiation from pluripotent stem cells using proteomics/PTMomics--current state-of-the-art and challenges
Q28085565	Choices for Induction of Pluripotency: Recent Developments in Human Induced Pluripotent Stem Cell Reprogramming Strategies
Q104139111	Cholesterol Lowering Drugs Reduce APP Processing to Aβ by Inducing APP Dimerization
Q64119879	Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons
Q37896762	Choreographing pluripotency and cell fate with transcription factors
Q91330211	Chromatin establishes an immature version of neuronal protocadherin selection during the naive-to-primed conversion of pluripotent stem cells
Q107101591	Chromosomal Instability and Karyotype Correction in Human Induced Pluripotent Stem Cells
Q104132650	Chromosomal aberration arises during somatic reprogramming to pluripotent stem cells
Q35595453	Chromosome microduplication in somatic cells decreases the genetic stability of human reprogrammed somatic cells and results in pluripotent stem cells
Q36904682	Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases
Q38165331	Clinical grade iPS cells: need for versatile small molecules and optimal cell sources
Q39024182	Clinical potential of human-induced pluripotent stem cells : Perspectives of induced pluripotent stem cells
Q35171879	Clinical therapy using iPSCs: hopes and challenges
Q41679189	Comparable frequencies of coding mutations and loss of imprinting in human pluripotent cells derived by nuclear transfer and defined factors
Q58595040	Comparative genomic analysis of embryonic, lineage-converted, and stem cell-derived motor neurons
Q35750530	Comparing ESC and iPSC-Based Models for Human Genetic Disorders
Q34147670	Comparison of the molecular profiles of human embryonic and induced pluripotent stem cells of isogenic origin
Q109928976	Comprehensive identification of somatic nucleotide variants in human brain tissue
Q38869345	Computational Tools for Stem Cell Biology.
Q50020156	Concise Review: Assessing the Genome Integrity of Human Induced Pluripotent Stem Cells: What Quality Control Metrics?
Q37633372	Concise Review: Getting to the Core of Inherited Bone Marrow Failures.
Q26799570	Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells
Q27004350	Concise review: Generation of neurons from somatic cells of healthy individuals and neurological patients through induced pluripotency or direct conversion
Q38235527	Concise review: Genomic instability in human stem cells: current status and future challenges.
Q37913263	Concise review: Genomic stability of human induced pluripotent stem cells
Q37993818	Concise review: Immune recognition of induced pluripotent stem cells.
Q37200221	Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products.
Q27025056	Concise review: Induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart?
Q34028987	Concise review: alchemy of biology: generating desired cell types from abundant and accessible cells
Q37680999	Concise review: drug discovery in the age of the induced pluripotent stem cell
Q38320762	Concise review: induced pluripotency by defined factors: prey of oxidative stress.
Q27013646	Concise review: pancreas regeneration: recent advances and perspectives
Q37635469	Concise review: parthenote stem cells for regenerative medicine: genetic, epigenetic, and developmental features
Q38197390	Concise review: pluripotent stem cell-based regenerative applications for failing β-cell function
Q26865173	Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes
Q33732794	Constraining the Pluripotent Fate of Human Embryonic Stem Cells for Tissue Engineering and Cell Therapy - The Turning Point of Cell-Based Regenerative Medicine
Q37879269	Constructing and deconstructing stem cell models of neurological disease
Q49649749	Context-Dependent and Disease-Specific Diversity in Protein Interactions within Stress Granules
Q34252601	Context-dependent enhancement of induced pluripotent stem cell reprogramming by silencing Puma
Q34381076	Controlling gene networks and cell fate with precision-targeted DNA-binding proteins and small-molecule-based genome readers
Q41030569	Converting Skin Fibroblasts into Hepatic-like Cells by Transient Programming
Q39310501	Copy number variations (CNVs) in human pluripotent cell-derived neuroprogenitors
Q36243930	CtIP-Specific Roles during Cell Reprogramming Have Long-Term Consequences in the Survival and Fitness of Induced Pluripotent Stem Cells
Q37183239	Current Biosafety Considerations in Stem Cell Therapy.
Q47102946	Current and Future Perspectives of Stem Cell Therapy in Dermatology.
Q27863418	Current and future therapeutic strategies for functional repair of spinal cord injury.
Q38287660	Current methods and challenges in the comprehensive characterization of human pluripotent stem cells.
Q37955461	Current progress and potential practical application for human pluripotent stem cells
Q38672652	Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells
Q89975352	Cyclooxygenases Inhibitors Efficiently Induce Cardiomyogenesis in Human Pluripotent Stem Cells
Q90152976	Cytogenetic Analysis of the Results of Genome Editing on the Cell Model of Parkinson's Disease
Q39286034	DNA Damage in Stem Cells
Q38045059	DNA double-strand break response in stem cells: mechanisms to maintain genomic integrity
Q37715647	DNA double-strand breaks in human induced pluripotent stem cell reprogramming and long-term in vitro culturing
Q35308217	Deep sequencing reveals low incidence of endogenous LINE-1 retrotransposition in human induced pluripotent stem cells
Q36171903	Defective antiviral responses of induced pluripotent stem cells to baculoviral vector transduction
Q26827732	Defining stem cell types: understanding the therapeutic potential of ESCs, ASCs, and iPS cells
Q33694696	Delayed epidural transplantation of human induced pluripotent stem cell-derived neural progenitors enhances functional recovery after stroke
Q37998955	Delineating nuclear reprogramming
Q88136828	Delivery systems of current biologicals for the treatment of chronic cutaneous wounds and severe burns
Q53540304	Demystifying the U.S. Food and Drug Administration: I. Understanding agency structure and function.
Q39352285	Dental Pulp Stem Cells for the study of Neurogenetic Disorders.
Q42818629	Derivation of human embryonic stem cells with NEMO deficiency
Q36391759	Derivation of integration-free iPSCs from a Klinefelter syndrome patient
Q39421324	Derivation of novel genetically diverse human embryonic stem cell lines
Q30472217	Detection and quantification of rare mutations with massively parallel sequencing
Q37968323	Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development
Q39262859	Development of experimental tumors formed by mouse and human embryonic stem and teratocarcinoma cells after subcutaneous and intraperitoneal transplantations into immunodeficient and immunocompetent mice.
Q36025246	Development of stem cell-based therapy for Parkinson's disease
Q34485165	Development of the endocrine pancreas and novel strategies for β-cell mass restoration and diabetes therapy
Q102382571	Differentiation of Human Parthenogenetic Embryonic Stem Cells into Functional Hepatocyte-like Cells
Q39362609	Differentiation of human pluripotent stem cells to retinal pigmented epithelium in defined conditions using purified extracellular matrix proteins
Q39561746	Differentiation of mouse induced pluripotent stem cells into neurons using conditioned medium of dorsal root ganglia
Q38117122	Direct cellular reprogramming in Caenorhabditis elegans: facts, models, and promises for regenerative medicine
Q38050228	Direct reprogramming of adult somatic cells into other lineages: past evidence and future perspectives
Q35823718	Direct, genome-wide assessment of DNA mutations in single cells.
Q38059468	Disease modelling using induced pluripotent stem cells: status and prospects
Q36023026	Distinctive features of single nucleotide alterations in induced pluripotent stem cells with different types of DNA repair deficiency disorders
Q42134030	Divergent Levels of Marker Chromosomes in an hiPSC-Based Model of Psychosis
Q37122515	Does transcription factor induced pluripotency accurately mimic embryo derived pluripotency?
Q39584237	Dopaminergic differentiation using pluripotent stem cells
Q99205780	Double sperm cloning (DSC) is a promising strategy in mammalian genetic engineering and stem cell research
Q52975832	Dynamic Variations in Genetic Integrity Accompany Changes in Cell Fate.
Q42197966	Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment
Q64983487	Dynamics of Telomere Rejuvenation during Chemical Induction to Pluripotent Stem Cells.
Q35031911	Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors
Q21134993	Ectopic PDX-1 expression directly reprograms human keratinocytes along pancreatic insulin-producing cells fate
Q35679665	Effects of Integrating and Non-Integrating Reprogramming Methods on Copy Number Variation and Genomic Stability of Human Induced Pluripotent Stem Cells
Q35473934	Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells
Q42521874	Efficient and simultaneous generation of hematopoietic and vascular progenitors from human induced pluripotent stem cells
Q35841510	Efficient derivation of human cardiac precursors and cardiomyocytes from pluripotent human embryonic stem cells with small molecule induction
Q35581854	Efficient derivation of human neuronal progenitors and neurons from pluripotent human embryonic stem cells with small molecule induction
Q35159151	Efficient differentiation of steroidogenic and germ-like cells from epigenetically-related iPSCs derived from ovarian granulosa cells
Q28477627	Efficient generation of fully reprogrammed human iPS cells via polycistronic retroviral vector and a new cocktail of chemical compounds
Q34738075	Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors
Q41021257	Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone.
Q45104521	Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells
Q35306023	Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells
Q34310404	Embedding the Future of Regenerative Medicine into the Open Epigenomic Landscape of Pluripotent Human Embryonic Stem Cells
Q101410235	Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges
Q36736355	Embryonic stem cells and inducible pluripotent stem cells: two faces of the same coin?
Q37627420	Embryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective
Q38724352	Emerging landscape of cell penetrating peptide in reprogramming and gene editing
Q38515964	Emerging roles of hypoxia-inducible factors and reactive oxygen species in cancer and pluripotent stem cells
Q38235439	Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014).
Q34239856	Empowering adult stem cells for myocardial regeneration
Q38178645	Endogenous cardiac stem cells for the treatment of heart failure
Q33940583	Energy metabolism in human pluripotent stem cells and their differentiated counterparts
Q36336579	Energy metabolism in nuclear reprogramming
Q38701434	Enhanced Identification of Transcriptional Enhancers Provides Mechanistic Insights into Diseases
Q36240798	Epigenetic rejuvenation.
Q38332689	Epigenetic-mediated reprogramming of pancreatic endocrine cells.
Q47562578	Epigenetics and cerebral organoids: promising directions in autism spectrum disorders
Q36296635	Equally potent? Does cellular reprogramming justify the abandonment of human embryonic stem cells?
Q36703082	Erosion of dosage compensation impacts human iPSC disease modeling
Q50050571	Ethical and Safety Issues of Stem Cell-Based Therapy.
Q39408692	Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes
Q37344013	Evolution of energy metabolism, stem cells and cancer stem cells: how the warburg and barker hypotheses might be linked.
Q38275520	Exploiting the unique regenerative capacity of the liver to underpin cell and gene therapy strategies for genetic and acquired liver disease.
Q38659473	Expression Pattern of Neuronal Markers in PB-MSCs Treated by Growth Factors Noggin, bFGF and EGF.
Q33989488	Extended passaging increases the efficiency of neural differentiation from induced pluripotent stem cells
Q49133610	FA iPS: correction or reprogramming first?
Q37055304	Fabrication of tissue-engineered vascular grafts with stem cells and stem cell-derived vascular cells
Q28550043	Familial Dysautonomia (FD) Human Embryonic Stem Cell Derived PNS Neurons Reveal that Synaptic Vesicular and Neuronal Transport Genes Are Directly or Indirectly Affected by IKBKAP Downregulation
Q34661781	Few single nucleotide variations in exomes of human cord blood induced pluripotent stem cells
Q38166000	From "ES-like" cells to induced pluripotent stem cells: a historical perspective in domestic animals.
Q27692698	From "directed differentiation" to "neuronal induction": modeling neuropsychiatric disease
Q38064949	From cellular therapies to tissue reprogramming and regenerative strategies in the treatment of diabetes
Q88954641	Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-β clearance in human astrocytes
Q92242441	Functional Oocytes Derived from Granulosa Cells
Q91135792	Functions of p53 in pluripotent stem cells
Q51551337	Future challenges for patient-specific induced pluripotent stem cells in cardiovascular medicine.
Q35235968	Future of liver transplantation: non-human primates for patient-specific organs from induced pluripotent stem cells
Q38932305	Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease
Q38559319	Gene Expression Studies on Human Trisomy 21 iPSCs and Neurons: Towards Mechanisms Underlying Down's Syndrome and Early Alzheimer's Disease-Like Pathologies
Q45874318	Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier
Q93162780	Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice
Q28535131	Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells
Q38882610	Generating hESCs with reduced immunogenicity by disrupting TAP1 or TAPBP.
Q39369030	Generating hypoimmunogenic human embryonic stem cells by the disruption of beta 2-microglobulin
Q27021372	Generating pluripotent stem cells: differential epigenetic changes during cellular reprogramming
Q35143768	Generation and characterization of induced pluripotent stem cells from Aid-deficient mice
Q39461603	Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells
Q93044889	Generation of Endothelial Cells From Human Pluripotent Stem Cells
Q48365947	Generation of Transplantable Retinal Photoreceptors from a Current Good Manufacturing Practice-Manufactured Human Induced Pluripotent Stem Cell Line.
Q51434679	Generation of a Functional Human Neural Network by NDM29 Overexpression in Neuroblastoma Cancer Cells.
Q36379316	Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells.
Q42236792	Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells.
Q28478987	Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells
Q36898895	Generation of human epidermis-derived mesenchymal stem cell-like pluripotent cells (hEMSCPCs)
Q34310664	Generation of human induced pluripotent stem cells from urine samples.
Q40807563	Generation of human induced pluripotent stem cells using non-synthetic mRNA.
Q45861515	Generation of iPSCs from genetically corrected Brca2 hypomorphic cells: implications in cell reprogramming and stem cell therapy
Q36458914	Generation of induced pluripotent stem cells from human Tenon's capsule fibroblasts
Q24631565	Generation of induced pluripotent stem cells from human renal proximal tubular cells with only two transcription factors, OCT4 and SOX2
Q30502509	Generation of induced pluripotent stem cells from urine
Q64390207	Generation of induced pluripotent stem cells without genetic defects by small molecules
Q37131138	Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression
Q39506695	Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations
Q45885275	Generation of systemic lupus erythematosus-specific induced pluripotent stem cells from urine
Q92563348	Genetic aberrations in iPSCs are introduced by a transient G1/S cell cycle checkpoint deficiency
Q49604645	Genetic and epigenetic factors which modulate differentiation propensity in human pluripotent stem cells
Q34316491	Genetic and epigenetic instability in human pluripotent stem cells.
Q38195438	Genetic and epigenetic instability of stem cells
Q38042359	Genetic and epigenetic stability of human pluripotent stem cells.
Q37139418	Genetic and epigenetic variations in iPSCs: potential causes and implications for application
Q34175757	Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy.
Q28544903	Genetic heterogeneity of induced pluripotent stem cells: results from 24 clones derived from a single C57BL/6 mouse
Q38110323	Genetic instability in human embryonic stem cells: prospects and caveats
Q40679668	Genetic instability in neural stem cells: an inconvenient truth?
Q38106717	Genetic instability of modified stem cells - a first step towards malignant transformation?
Q88729417	Genetics, genomics and the power of stem cells to identify novel treatment options in complex diseases
Q64814725	Genome Editing and the Problem of Tetraploidy in Cell Modeling of the Genetic Form of Parkinsonism
Q38061614	Genome damage in induced pluripotent stem cells: assessing the mechanisms and their consequences
Q38113338	Genome editing of human pluripotent stem cells to generate human cellular disease models
Q30413933	Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming
Q50058347	Genome stability of programmed stem cell products
Q26800186	Genome-editing tools for stem cell biology
Q51848794	Genome-wide dynamic changes of DNA methylation of repetitive elements in human embryonic stem cells and fetal fibroblasts.
Q92394646	Genomic Instability of iPSCs and Challenges in Their Clinical Applications
Q38945910	Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications
Q34437293	Genomic editing tools to model human diseases with isogenic pluripotent stem cells
Q84942448	Genomic instability in cultured stem cells: associated risks and underlying mechanisms
Q34699718	Genomic instability in iPS: time for a break
Q37596254	Genomic instability in pluripotent stem cells: implications for clinical applications
Q38240807	Genomic instability, driver genes and cell selection: Projections from cancer to stem cells
Q95652430	Genomic integrity of human induced pluripotent stem cells across nine studies in the NHLBI NextGen program
Q91141603	Genomic integrity of human induced pluripotent stem cells: Reprogramming, differentiation and applications
Q38725060	Genomic stability during cellular reprogramming: Mission impossible?
Q38049785	Genomic stability in reprogramming
Q37876900	Genomics and the eye.
Q46900710	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies
Q37684345	Glial progenitor cell-based treatment of the childhood leukodystrophies
Q38184422	Great expectations: autism spectrum disorder and induced pluripotent stem cell technologies
Q100558883	Growth factors-based beneficial effects of platelet lysate on umbilical cord-derived stem cells and their synergistic use in osteoarthritis treatment
Q47154700	HIF1α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2.
Q38186557	HIV/AIDS: modified stem cells in the spotlight
Q36160823	HLA Class I Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications
Q34182222	Harnessing the potential of induced pluripotent stem cells for regenerative medicine
Q38644646	Heart regeneration.
Q27001570	Hematopoietic stem cell engineering at a crossroads
Q34212796	Hematopoietic, CNS and skeletal muscle stem cells as drug targets: opportunities, progress and challenges
Q28533511	Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients
Q64389495	High Basal Levels of γH2AX in Human Induced Pluripotent Stem Cells Are Linked to Replication-Associated DNA Damage and Repair
Q83430534	High prevalence of evolutionarily conserved and species-specific genomic aberrations in mouse pluripotent stem cells
Q28595764	High-Fidelity Reprogrammed Human IPSCs Have a High Efficacy of DNA Repair and Resemble hESCs in Their MYC Transcriptional Signature
Q38707631	High-Throughput and Cost-Effective Characterization of Induced Pluripotent Stem Cells.
Q93084676	Highlight report: the need of 'fit-for-purpose' controls for cell lines used in toxicity assays
Q47718139	Historical Perspectives and Advances in Mesenchymal Stem Cell Research for the Treatment of Liver Diseases
Q34332168	Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state
Q47666594	Hotspots of De Novo Point Mutations in Induced Pluripotent Stem Cells.
Q39520448	How can ethics relate to science? The case of stem cell research
Q45342933	Human Amnion-Derived Stem Cells Have Immunosuppressive Properties on NK Cells and Monocytes
Q36841874	Human ESC/iPSC-based "Omics" and Bioinformatics for Translational Research
Q38782443	Human Induced Pluripotent Stem Cell-Derived Motor Neuron Transplant for Neuromuscular Atrophy in a Mouse Model of Sciatic Nerve Injury
Q102376774	Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
Q35640330	Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis.
Q89527595	Human artificial chromosomes for pluripotent stem cell-based tissue replacement therapy
Q38032401	Human disease modeling with induced pluripotent stem cells
Q37911584	Human embryonic stem cell-derived vascular smooth muscle cells in therapeutic neovascularisation
Q37344763	Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders
Q34085826	Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination
Q94512655	Human induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies
Q39247913	Human induced pluripotent stem cells for modelling neurodevelopmental disorders.
Q39512046	Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming
Q39298289	Human induced pluripotent stem cells improve stroke outcome and reduce secondary degeneration in the recipient brain
Q35789181	Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling
Q38014251	Human induced pluripotent stem cells--from mechanisms to clinical applications
Q34417577	Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells
Q28249896	Human oocytes reprogram somatic cells to a pluripotent state
Q37924272	Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective
Q37950950	Human pluripotent stem cells for disease modelling and drug screening
Q37931912	Human pluripotent stem cells for genetic disease modeling and drug screening.
Q27005360	Human pluripotent stem cells for modelling human liver diseases and cell therapy
Q34325210	Human pluripotent stem cells: an emerging model in developmental biology.
Q36193696	Human pluripotent stem cells: applications and challenges in neurological diseases.
Q58666481	Human procreation in unchartered territory: new twists in ethical discussions
Q28072510	Human regeneration: An achievable goal or a dream?
Q53666332	Human somatic cell reprogramming: does the egg know best?
Q38732807	Human stem cell modeling in neurofibromatosis type 1 (NF1).
Q33788845	Human stem cells for craniomaxillofacial reconstruction.
Q37996797	Human umbilical cord is a unique and safe source of various types of stem cells suitable for treatment of hematological diseases and for regenerative medicine
Q38332930	Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy
Q41420025	Identification of a Gene Encoding Slow Skeletal Muscle Troponin T as a Novel Marker for Immortalization of Retinal Pigment Epithelial Cells.
Q51359431	Identification of a High-Frequency Somatic NLRC4 Mutation as a Cause of Autoinflammation by Pluripotent Cell-Based Phenotype Dissection.
Q31092974	Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells
Q110698454	Identification of cancer-related mutations in human pluripotent stem cells using RNA-seq analysis
Q39144719	Identification of unsafe human induced pluripotent stem cell lines using a robust surrogate assay for pluripotency
Q61796420	Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs
Q39193150	Immediate expression of Cdh2 is essential for efficient neural differentiation of mouse induced pluripotent stem cells.
Q29616185	Immunogenicity of induced pluripotent stem cells
Q36802900	Immunogenicity of pluripotent stem cells and their derivatives
Q39446999	Immunological Issues After Stem Cell-Based β Cell Replacement
Q35623479	Immunoreactivity of Pluripotent Markers SSEA-5 and L1CAM in Human Tumors, Teratomas, and Induced Pluripotent Stem Cells
Q34385134	Implications and limitations of cellular reprogramming for psychiatric drug development
Q36208256	Implications of aneuploidy for stem cell biology and brain therapeutics
Q48663615	Impracticality of egg donor recruitment in the absence of compensation
Q38696341	In Vitro Developmental Toxicology Screens: A Report on the Progress of the Methodology and Future Applications
Q35775664	In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases
Q28485241	In vivo cell reprogramming towards pluripotency by virus-free overexpression of defined factors
Q33951804	In vivo reprogramming of adult somatic cells to pluripotency by overexpression of Yamanaka factors
Q48642408	Increased cleavage rate of human nuclear transfer embryos after 5-aza-2'-deoxycytidine treatment.
Q57562675	Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency
Q33551989	Increased genomic integrity of an improved protein-based mouse induced pluripotent stem cell method compared with current viral-induced strategies
Q38655654	Induced Pluripotency and Epigenetic Reprogramming
Q26775061	Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges
Q91872831	Induced Pluripotent Stem Cells (iPSCs) in Developmental Toxicology
Q38116769	Induced Pluripotent Stem Cells and Disorders of the Nervous System: Progress, Problems, and Prospects
Q26777488	Induced Pluripotent Stem Cells and Periodontal Regeneration
Q57454780	Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Q89010083	Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association
Q37592612	Induced Pluripotent Stem Cells for Traumatic Spinal Cord Injury
Q38569134	Induced Pluripotent Stem Cells: A New Frontier for Stem Cells in Dentistry.
Q41660631	Induced Pluripotent Stem Cells: Advances in the Quest for Genetic Stability during Reprogramming Process
Q38110478	Induced neural stem cells (iNSCs) in neurodegenerative diseases
Q37265783	Induced pluripotent stem (iPS) cells from human fetal stem cells (hFSCs).
Q38205616	Induced pluripotent stem (iPS) cells: a new source for cell-based therapeutics?
Q39402516	Induced pluripotent stem cell clones reprogrammed via recombinant adeno-associated virus-mediated transduction contain integrated vector sequences
Q37564317	Induced pluripotent stem cell generation-associated point mutations arise during the initial stages of the conversion of these cells
Q33830512	Induced pluripotent stem cell models of lysosomal storage disorders
Q37988757	Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening.
Q38097412	Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research
Q37914472	Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises
Q91744586	Induced pluripotent stem cells and derivative photoreceptor precursors as therapeutic cells for retinal degenerations
Q37995010	Induced pluripotent stem cells and severe combined immunodeficiency: merely disease modeling or potentially a novel cure?
Q35126519	Induced pluripotent stem cells are induced pluripotent stem cell-like cells
Q35171927	Induced pluripotent stem cells are sensitive to DNA damage
Q26865689	Induced pluripotent stem cells as a disease modeling and drug screening platform
Q38203865	Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges.
Q27000647	Induced pluripotent stem cells from ALS patients for disease modeling
Q42819897	Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery
Q26772879	Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges
Q38603881	Induced pluripotent stem cells in cardiovascular medicine
Q37996912	Induced pluripotent stem cells in cardiovascular research
Q38007342	Induced pluripotent stem cells in clinical hematology: potentials, progress, and remaining obstacles
Q34400271	Induced pluripotent stem cells in dermatology: potentials, advances, and limitations
Q55113434	Induced pluripotent stem cells in reproductive medicine.
Q28484399	Induced pluripotent stem cells show metabolomic differences to embryonic stem cells in polyunsaturated phosphatidylcholines and primary metabolism
Q84242212	Induced pluripotent stem cells--a cautionary note
Q34231818	Induced pluripotent stem cells--opportunities for disease modelling and drug discovery
Q35205657	Induced pluripotent stem cells: Mechanisms, achievements and perspectives in farm animals
Q37857439	Induced pluripotent stem cells: a new revolution for clinical neurology?
Q37392636	Induced pluripotent stem cells: origins, applications, and future perspectives
Q34281955	Induced pluripotent stem cells: past, present, and future
Q34303709	Induced pluripotent stem cells: the new patient?
Q36405220	Inducing iPSCs to escape the dish.
Q40911800	Influence of ATM-Mediated DNA Damage Response on Genomic Variation in Human Induced Pluripotent Stem Cells
Q39603765	Inhibition of glycogen synthase kinase-3 promotes efficient derivation of pluripotent stem cells from neonatal mouse testis.
Q38609236	Initial embryology and pluripotent stem cells in the pig--The quest for establishing the pig as a model for cell therapy.
Q110696924	Insertion/deletion and microsatellite alteration profiles in induced pluripotent stem cells
Q90468480	Insights into the Mutational Burden of Human Induced Pluripotent Stem Cells from an Integrative Multi-Omics Approach
Q38187779	Instant neurons: directed somatic cell reprogramming models of central nervous system disorders
Q35285830	Insulin-producing surrogate β-cells from embryonic stem cells: are we there yet?
Q57178582	Interfacial tissue engineering of heart regenerative medicine based on soft cell-porous scaffolds
Q33892673	Intramyocardial transplantation of undifferentiated rat induced pluripotent stem cells causes tumorigenesis in the heart
Q36512584	Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells
Q34431170	Investigating human disease using stem cell models
Q26822991	Investigation of Rett syndrome using pluripotent stem cells
Q96613404	Invited contribution to the volume: "Stem cells & cancer stem cells, regenerative medicine & cancer" (VSI stem cells) reprogramming and transdifferentiation - two key processes for regenerative medicine
Q38130450	Is aging a barrier to reprogramming? Lessons from induced pluripotent stem cells
Q47315378	Isl1β over-expression with key β cell transcription factors enhances glucose-responsive hepatic insulin production and secretion
Q34038853	Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome
Q37508350	JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia
Q36934047	Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells.
Q38630042	L1 Mosaicism in Mammals: Extent, Effects, and Evolution.
Q46188771	Large-Scale Targeted DNA Methylation Analysis Using Bisulfite Padlock Probes
Q39495087	Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells
Q33419236	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.
Q34151119	Library-free methylation sequencing with bisulfite padlock probes
Q36030065	Limiting replication stress during somatic cell reprogramming reduces genomic instability in induced pluripotent stem cells
Q28254408	Long-term culture of genome-stable bipotent stem cells from adult human liver
Q93012197	Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells
Q38834610	Looking to the future following 10 years of induced pluripotent stem cell technologies
Q60621312	Low expression of activin a in mouse and human embryonic teratocarcinoma cells
Q39066271	Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Q34030950	Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression
Q33849553	Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing.
Q64389181	Lower genomic stability of induced pluripotent stem cells reflects increased non-homologous end joining
Q57293352	Major changes of cell function and toxicant sensitivity in cultured cells undergoing mild, quasi-natural genetic drift
Q48654476	Making it personal: the prospects for autologous pluripotent stem cell-derived therapies.
Q38657159	Manufacturing Cell Therapies Using Engineered Biomaterials.
Q34699015	Maturing from embryonic to adult policy on stem cell therapeutics
Q37953325	Mechanism and methods to induce pluripotency
Q34345169	Mechanisms and models of somatic cell reprogramming
Q39235512	Medicine. iPSC disease modeling
Q47576382	Mesenchymal stem cells for peripheral nerve regeneration--a real hope or just an empty promise?
Q21132551	Mesenchymal-to-endothelial transition in Kaposi sarcoma: a histogenetic hypothesis based on a case series and literature review
Q40095667	Messenger RNA- versus retrovirus-based induced pluripotent stem cell reprogramming strategies: analysis of genomic integrity.
Q34035168	MicroRNAs in somatic cell reprogramming
Q92994195	Mitochondrial genome mutations in mesenchymal stem cells derived from human dental induced pluripotent stem cells
Q28477951	Mitochondrial-associated cell death mechanisms are reset to an embryonic-like state in aged donor-derived iPS cells harboring chromosomal aberrations
Q26996543	Modeling AEC-New approaches to study rare genetic disorders
Q98469013	Modeling ALS using iPSCs: Is it possible to reproduce the phenotypic variations observed in patients in vitro?
Q92881218	Modeling Leukemia with Human Induced Pluripotent Stem Cells
Q48323464	Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations
Q91410795	Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs
Q27687330	Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells.
Q38256754	Modeling human disease phenotype in model organisms: "It's only a model!".
Q92330251	Modeling neuropsychiatric disorders using human induced pluripotent stem cells
Q30446669	Modeling psychiatric disorders at the cellular and network levels
Q35665016	Modeling psychiatric disorders through reprogramming
Q58570905	Modelling Sporadic Alzheimer's Disease Using Induced Pluripotent Stem Cells
Q26864380	Modelling human disease with pluripotent stem cells
Q36655275	Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes
Q37702648	Mouse SCNT ESCs have lower somatic mutation load than syngeneic iPSCs
Q38037458	Mouse-induced pluripotent stem cells
Q28828176	Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch
Q34294018	Mutation frequency dynamics in HPRT locus in culture-adapted human embryonic stem cells and induced pluripotent stem cells correspond to their differentiated counterparts
Q38088548	Mutation rate in stem cells: an underestimated barrier on the way to therapy
Q35982232	Mutational History of a Human Cell Lineage from Somatic to Induced Pluripotent Stem Cells
Q41136531	Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation
Q26999246	Myocardial cell sheet therapy and cardiac function
Q26799633	Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
Q59334977	Need for high-resolution Genetic Analysis in iPSC: Results and Lessons from the ForIPS Consortium
Q34321823	Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells
Q35576478	Neural stem cells: historical perspective and future prospects.
Q52729618	Neuronal replacement therapy: previous achievements and challenges ahead.
Q89067065	Neurotransplantation therapy
Q110698679	Neurotrophic Factors Secreted by Induced Pluripotent Stem Cell-Derived Retinal Progenitors Promote Retinal Survival and Preservation in an Adult Porcine Neuroretina Model
Q38999345	Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy
Q38777299	New Insights into Diabetes Cell Therapy.
Q37998144	New York State's landmark policies on oversight and compensation for egg donation to stem cell research
Q52372478	New considerations for hiPSC-based models of neuropsychiatric disorders.
Q36945734	New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells
Q36389277	New frontiers in human cell biology and medicine: can pluripotent stem cells deliver?
Q38041766	New insights into cell cycle regulation and DNA damage response in embryonic stem cells
Q36374130	New lessons learned from disease modeling with induced pluripotent stem cells
Q33716184	Next-generation sequencing traces human induced pluripotent stem cell lines clonally generated from heterogeneous cancer tissue
Q42566630	Non-viral iPSCs: a safe way for therapy?
Q38012256	Nonclinical safety strategies for stem cell therapies.
Q35027623	Notch inhibition allows oncogene-independent generation of iPS cells
Q92746888	Novel patient-derived preclinical models of liver cancer
Q38049346	Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
Q38217352	Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
Q34976119	Nucleosome organizations in induced pluripotent stem cells reprogrammed from somatic cells belonging to three different germ layers
Q33826505	Oct4 cell-autonomously promotes primitive endoderm development in the mouse blastocyst
Q28511152	Oct4 interaction with Hmgb2 regulates Akt signaling and pluripotency
Q110597984	Off-the-Shelf, Immune-Compatible Human Embryonic Stem Cells Generated Via CRISPR-Mediated Genome Editing
Q58785850	On the Viability and Potential Value of Stem Cells for Repair and Treatment of Central Neurotrauma: Overview and Speculations
Q38201281	On the road to bioartificial organs
Q40446420	One thousand somatic SNVs per skin fibroblast cell set baseline of mosaic mutational load with patterns that suggest proliferative origin.
Q35750557	Opportunities and Limitations of Modelling Alzheimer's Disease with Induced Pluripotent Stem Cells
Q38669103	Organoids derived from digestive tract, liver, and pancreas
Q37693830	Origins and implications of pluripotent stem cell variability and heterogeneity
Q27014026	Overcoming barriers to the clinical utilization of iPSCs: reprogramming efficiency, safety and quality
Q28083762	Overcoming the hurdles for a reproducible generation of human functionally mature reprogrammed neurons
Q34017629	Oxamflatin significantly improves nuclear reprogramming, blastocyst quality, and in vitro development of bovine SCNT embryos
Q37971244	Oxidative stress-induced biomarkers for stem cell-based chemical screening
Q110695934	Oxygen as a Master Regulator of Human Pluripotent Stem Cell Function and Metabolism
Q42562656	Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?
Q45764055	Passage-dependent accumulation of somatic mutations in mesenchymal stromal cells during in vitro culture revealed by whole genome sequencing.
Q35095120	Path from schizophrenia genomics to biology: gene regulation and perturbation in neurons derived from induced pluripotent stem cells and genome editing
Q37264786	Pathological classification of human iPSC-derived neural stem/progenitor cells towards safety assessment of transplantation therapy for CNS diseases
Q57155504	Patient-Derived Stem Cell Models in HSP: Disease Modelling and Drug Discovery
Q35911310	Perspectives on cell reprogramming with RNA.
Q39044287	Phenotypic assays for analyses of pluripotent stem cell-derived cardiomyocytes
Q38009793	Physiological aspects of cardiac tissue engineering
Q37014278	Physiological, pathological, and engineered cell identity reprogramming in the central nervous system
Q54526548	Picking the lock on pluripotency.
Q34503625	Pluripotency and its layers of complexity
Q90260270	Pluripotent Stem Cell Heterogeneity
Q100421431	Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges
Q37869018	Pluripotent human stem cells for the treatment of retinal disease
Q90714292	Pluripotent stem cell replacement approaches to treat type 1 diabetes
Q37998452	Pluripotent stem cell-based cancer therapy: promise and challenges
Q37997987	Pluripotent stem cell-based heart regeneration: from the developmental and immunological perspectives
Q52589683	Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.
Q34226123	Pluripotent stem cells for the study of CNS development
Q26999292	Pluripotent stem cells in regenerative medicine: challenges and recent progress
Q38910429	Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI).
Q27329876	Porcine induced pluripotent stem cells require LIF and maintain their developmental potential in early stage of embryos
Q46095147	Position statement on the provision and procurement of human eggs for stem cell research
Q26799621	Potential Role of Induced Pluripotent Stem Cells (IPSCs) for Cell-Based Therapy of the Ocular Surface
Q33999335	Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy.
Q38003694	Potential for pharmacological manipulation of human embryonic stem cells.
Q37907893	Potential pathways to restore β-cell mass: pluripotent stem cells, reprogramming, and endogenous regeneration
Q97423548	Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease
Q91781932	Precision Health Resource of Control iPSC Lines for Versatile Multilineage Differentiation
Q97540541	Precision installation of a highly efficient suicide gene safety switch in human induced pluripotent stem cells
Q60018180	Preclinical animal models for testing iPSC/ESC-based heart therapy
Q37596291	Preclinical studies for induced pluripotent stem cell-based therapeutics
Q36492596	Present and future cell therapies for pancreatic beta cell replenishment
Q96438728	Prime time for primate functional genomics
Q51860862	Primer and interviews: promises and realities of induced pluripotent stem cells.
Q21560913	Production of embryonic and fetal-like red blood cells from human induced pluripotent stem cells
Q104612386	Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease
Q28652287	Progress and bottleneck in induced pluripotency
Q38012401	Promise and challenges of human iPSC-based hematologic disease modeling and treatment
Q35981059	Promotion of the induction of cell pluripotency through metabolic remodeling by thyroid hormone triiodothyronine-activated PI3K/AKT signal pathway
Q37997007	Prospect of induced pluripotent stem cell genetic repair to cure genetic diseases
Q38035454	Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells
Q37934739	Prospects for pluripotent stem cell therapies: into the clinic and back to the bench
Q39495347	Prospects of Stem Cells for Retinal Diseases
Q47204137	Psychiatry in a Dish: Stem Cells and Brain Organoids Modeling Autism Spectrum Disorders.
Q35807504	Purinergic signaling in human pluripotent stem cells is regulated by the housekeeping gene encoding hypoxanthine guanine phosphoribosyltransferase
Q50429399	Quality control towards the application of induced pluripotent stem cells
Q38180443	Quality control: Genome maintenance in pluripotent stem cells
Q38839000	Quantifying signaling pathway activation to monitor the quality of induced pluripotent stem cells
Q34242167	ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells
Q41115761	Rad51 Regulates Reprogramming Efficiency through DNA Repair Pathway
Q27342678	Rapid and efficient conversion of integration-free human induced pluripotent stem cells to GMP-grade culture conditions
Q33717760	Recapitulating and Correcting Marfan Syndrome in a Cellular Model
Q38259068	Recellularization of organs: what is the future for solid organ transplantation?
Q26767096	Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells
Q49894761	Recent Advances in Retinal Stem Cell Therapy.
Q90662510	Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy
Q110699042	Recent advances in the induced pluripotent stem cell‐based skin regeneration
Q36341467	Recurrent transcriptional clusters in the genome of mouse pluripotent stem cells
Q39456273	Recurrent trisomy and Robertsonian translocation of chromosome 14 in murine iPS cell lines
Q35947502	Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives.
Q34368977	Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations
Q34399774	Regenerative medicine for the heart: perspectives on stem-cell therapy
Q38075104	Regenerative medicine for the treatment of heart disease
Q42324030	Regenerative medicine using dental pulp stem cells for liver diseases
Q48953873	Regenerative medicine: Bespoke cells for the human brain
Q35939439	Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer
Q64076034	Relevance and Recent Developments of Chitosan in Peripheral Nerve Surgery
Q38116204	Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders
Q38491734	Repairing organs: lessons from intestine and liver
Q38443588	Repressors of reprogramming
Q47575364	Reprint of "iPSCs, aging and age-related diseases".
Q36776248	Reprogrammed cells for disease modeling and regenerative medicine
Q38177409	Reprogramming and carcinogenesis--parallels and distinctions
Q38099079	Reprogramming and the pluripotent stem cell cycle
Q38127702	Reprogramming and transdifferentiation shift the landscape of regenerative medicine
Q35216812	Reprogramming antitumor immunity
Q38567265	Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling?
Q39433954	Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells
Q35156623	Reprogramming for cardiac regeneration.
Q50618152	Reprogramming of somatic cells: iPS and iN cells.
Q35605212	Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility
Q28483105	Reprogramming to pluripotency can conceal somatic cell chromosomal instability
Q36511186	Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cells
Q91381594	Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations
Q37159009	Reshaping the brain: direct lineage conversion in the nervous system
Q28484378	Residual expression of reprogramming factors affects the transcriptional program and epigenetic signatures of induced pluripotent stem cells
Q37898919	Restoring neuronal function after stroke by cell replacement: anatomic and functional considerations
Q36998497	Return of results in translational iPS cell research: considerations for donor informed consent
Q28652863	Reversible mitochondrial DNA accumulation in nuclei of pluripotent stem cells
Q38862587	Review: Induced pluripotent stem cell models of frontotemporal dementia
Q92994162	Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector
Q38042456	Role of mass spectrometry-based proteomics in the study of cellular reprogramming and induced pluripotent stem cells
Q38270850	Role of nanotechnology in epigenetic reprogramming
Q33752469	Role of tumor suppressor genes in the cancer-associated reprogramming of human induced pluripotent stem cells
Q42177878	SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts
Q34569517	SIMPLE MACHINE PERFUSION SIGNIFICANTLY ENHANCES HEPATOCYTE YIELDS OF ISCHEMIC AND FRESH RAT LIVERS.
Q90027602	SNV identification from single-cell RNA sequencing data
Q41863028	SOX9 as a Predictor for Neurogenesis Potentiality of Amniotic Fluid Stem Cells
Q36906143	Safeguarding clinical translation of pluripotent stem cells with suicide genes
Q36403953	Screening of human pluripotent stem cells using CGH and FISH reveals low-grade mosaic aneuploidy and a recurrent amplification of chromosome 1q.
Q84248049	Searching for new cardiovascular drugs: towards improved systems for drug screening?
Q34044765	Self-Destruct Genetic Switch to Safeguard iPS Cells
Q38216498	Self-renewal and cell lineage differentiation strategies in human embryonic stem cells and induced pluripotent stem cells.
Q55514058	Sheep embryonic stem-like cells engrafted into sheep femoral condyle osteochondral defects: 4-year follow-up.
Q36379464	Simultaneous Reprogramming and Gene Correction of Patient Fibroblasts
Q52431349	Simultaneous reprogramming and gene editing of human fibroblasts.
Q92520736	Single cell-derived clonally expanded mesenchymal progenitor cells from somatic cell nuclear transfer-derived pluripotent stem cells ameliorate the endometrial function in the uterus of a murine model with Asherman's syndrome
Q46211043	Single-Cell Alternative Splicing Analysis with Expedition Reveals Splicing Dynamics during Neuron Differentiation
Q48251179	Sirt6 Promotes DNA End Joining in iPSCs Derived from Old Mice
Q35657562	Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells
Q42541533	Small but significant: inter- and intrapatient variations in iPS cell-based disease modeling
Q37111537	Small molecules affect human dental pulp stem cell properties via multiple signaling pathways
Q91618848	Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD
Q34031127	Somatic cell reprogramming for regenerative medicine: SCNT vs. iPS cells
Q36861555	Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent
Q51765885	Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein.
Q37976119	Standardization of pluripotent stem cell cultures for toxicity testing
Q48774892	State-of-the-Art in Tissue-Engineered Heart Repair
Q45960691	Steady advance of stem cell therapies: report from the 2011 World Stem Cell Summit, Pasadena, California, October 3-5.
Q38595986	Stem Cells in Skeletal Tissue Engineering: Technologies and Models.
Q37643268	Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking
Q31017177	Stem cell biology and drug discovery.
Q35626316	Stem cell pathologies and neurological disease
Q27028106	Stem cell sources for vascular tissue engineering and regeneration
Q37958579	Stem cell technology for drug discovery and development
Q35224202	Stem cell technology for neurodegenerative diseases.
Q98467458	Stem cell therapies for retinal diseases: from bench to bedside
Q37995019	Stem cell therapy for cardiac disease
Q36836349	Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology
Q38225999	Stem cell therapy: challenges ahead
Q84918562	Stem cell toxicity?
Q42698079	Stem cells and heart disease - brake or accelerator?
Q38064947	Stem cells and neurodegenerative diseases: where is it all going?
Q52604329	Stem cells and regenerative medicine for neural repair.
Q37885081	Stem cells and the endocrine pancreas
Q38072498	Stem cells and the treatment of Parkinson's disease
Q37977735	Stem cells as a potential therapy for epilepsy
Q38341972	Stem cells for amyotrophic lateral sclerosis modeling and therapy: myth or fact?
Q33352048	Stem cells for cardiac repair in acute myocardial infarction
Q38205896	Stem cells for osteodegenerative diseases: current studies and future outlook
Q37938917	Stem cells for retinal replacement therapy
Q26828014	Stem cells in retinal regeneration: past, present and future
Q39591324	Stem cells, science, and public reasoning
Q83567372	Stem cells: Reprogramming's unintended consequences
Q84143735	Stem cells: The growing pains of pluripotency
Q42852853	Stemming our irrational exuberance
Q34325607	Steps toward safe cell therapy using induced pluripotent stem cells
Q103831501	Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines
Q26852277	Strategies for Oral Mucosal Repair by Engineering 3D Tissues with Pluripotent Stem Cells
Q38677976	Strategies for bringing stem cell-derived dopamine neurons to the clinic: The Kyoto trial
Q37968752	Strategies for replacing myocytes with induced pluripotent stem in clinical protocols
Q42180819	Striatal Transplantation of Human Dopaminergic Neurons Differentiated From Induced Pluripotent Stem Cells Derived From Umbilical Cord Blood Using Lentiviral Reprogramming
Q88618417	Survival of syngeneic and allogeneic iPSC-derived neural precursors after spinal grafting in minipigs
Q64447207	Synthetic Biology Approaches for Regenerative Medicine
Q38040207	Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury.
Q31044390	Systematic search for recipes to generate induced pluripotent stem cells
Q37602633	TGF-β1-induced differentiation of SHED into functional smooth muscle cells.
Q91468844	TGFβ Family Signaling Pathways in Pluripotent and Teratocarcinoma Stem Cells' Fate Decisions: Balancing Between Self-Renewal, Differentiation, and Cancer
Q26799625	Tapping Stem Cells to Target AMD: Challenges and Prospects
Q43179664	Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells
Q41874924	Targeted gene therapy and cell reprogramming in Fanconi anemia
Q36588964	Targeted single molecule mutation detection with massively parallel sequencing
Q41674738	Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.
Q38074176	Technological overview of iPS induction from human adult somatic cells
Q38707524	Telomere dynamics in dyskeratosis congenita: the long and the short of iPS.
Q35563251	Telomere dynamics in induced pluripotent stem cells: Potentials for human disease modeling
Q38953436	Temporal analysis of genome alterations induced by single-cell passaging in human embryonic stem cells
Q39317413	Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming
Q110695858	The Application of Induced Pluripotent Stem Cells Against Liver Diseases: An Update and a Review
Q34398856	The B-MYB transcriptional network guides cell cycle progression and fate decisions to sustain self-renewal and the identity of pluripotent stem cells
Q84863227	The First AACR special conference on stem cells, development, and cancer: some of these cells are not like the others
Q33753295	The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives
Q110695821	The Impact of Acquired Genetic Abnormalities on the Clinical Translation of Human Pluripotent Stem Cells
Q48199192	The Number of Point Mutations in Induced Pluripotent Stem Cells and Nuclear Transfer Embryonic Stem Cells Depends on the Method and Somatic Cell Type Used for Their Generation
Q110698354	The Potential of Induced Pluripotent Stem Cells to Treat and Model Alzheimer's Disease
Q38722713	The Therapeutic Potential of Cell Identity Reprogramming for the Treatment of Aging-Related Neurodegenerative Disorders
Q90321550	The application of in vitro-derived human neurons in neurodegenerative disease modeling
Q84435170	The beat goes on: human heart muscle from pluripotent stem cells
Q59048452	The dark side of induced pluripotency
Q34222768	The developmental potential of iPSCs is greatly influenced by reprogramming factor selection
Q42792252	The distribution of genomic variations in human iPSCs is related to replication-timing reorganization during reprogramming.
Q38192029	The epigenome in pluripotency and differentiation.
Q89553658	The evolution of stem cells, disease modeling, and drug discovery for neurological disorders
Q38024317	The evolving field of induced pluripotency: recent progress and future challenges
Q38058682	The expanding scope of DNA sequencing
Q36741613	The expanding world of tissue engineering: the building blocks and new applications of tissue engineered constructs
Q36283235	The gene expression profiles of induced pluripotent stem cells (iPSCs) generated by a non-integrating method are more similar to embryonic stem cells than those of iPSCs generated by an integrating method
Q36632900	The gene expression profiles of induced pluripotent stem cells from individuals with childhood cerebral adrenoleukodystrophy are consistent with proposed mechanisms of pathogenesis
Q26998764	The genomic stability of induced pluripotent stem cells
Q36799509	The genomically mosaic brain: aneuploidy and more in neural diversity and disease
Q36627127	The hematopoietic system in the context of regenerative medicine
Q37887868	The human brain in a dish: the promise of iPSC-derived neurons
Q64112074	The impact of transposable element activity on therapeutically relevant human stem cells
Q41420972	The labyrinth of nuclear reprogramming
Q37137826	The landscape of DNA methylation amid a perfect storm of autism aetiologies.
Q33972702	The living-tissue microscope: the importance of studying stem cells in their natural, undisturbed microenvironment
Q64914852	The march of pluripotent stem cells in cardiovascular regenerative medicine.
Q89543326	The mesenchymoangioblast, mesodermal precursor for mesenchymal and endothelial cells
Q35656245	The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming
Q89129290	The miR-590/Acvr2a/Terf1 Axis Regulates Telomere Elongation and Pluripotency of Mouse iPSCs
Q34038389	The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele
Q35375977	The p53-PUMA axis suppresses iPSC generation
Q38011958	The path from skin to brain: generation of functional neurons from fibroblasts
Q26851666	The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies
Q33356360	The potential for stem cells in cerebral palsy--piecing together the puzzle
Q38260092	The potential of alternate sources of cells for neural grafting in Parkinson's and Huntington's disease
Q38750644	The potential of induced pluripotent stem cell derived hepatocytes
Q35981667	The potential of induced pluripotent stem cells as a translational model for neurotoxicological risk
Q34095423	The potential of stem cell-based therapy for retinal repair
Q37401120	The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells
Q36965820	The promise and challenges of stem cell-based therapies for skeletal diseases: stem cell applications in skeletal medicine: potential, cell sources and characteristics, and challenges of clinical translation
Q35166105	The promise of human embryonic stem cells in aging-associated diseases
Q34281949	The propensity for tumorigenesis in human induced pluripotent stem cells is related with genomic instability
Q57083118	The quest for the perfect reprogrammed cell
Q84749994	The rejection barrier to induced pluripotent stem cells
Q38046388	The role of DNA repair in the pluripotency and differentiation of human stem cells.
Q35558500	The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases
Q87852155	The role of the reprogramming method and pluripotency state in gamete differentiation from patient-specific human pluripotent stem cells
Q38116677	The root of reduced fertility in aged women and possible therapentic options: current status and future perspects.
Q38804965	The significance of cell-related challenges in the clinical application of tissue engineering.
Q50954845	The sixth annual translational stem cell research conference of the New York Stem Cell Foundation.
Q41889645	The stability of the induced epigenetic programs
Q28247457	The stuttering progress of cell therapy for heart disease
Q37666286	The translational potential of human induced pluripotent stem cells for clinical neurology : The translational potential of hiPSCs in neurology
Q37851350	The tumorigenicity of human embryonic and induced pluripotent stem cells
Q35616186	The use of pluripotent stem cell for personalized cell therapies against neurological disorders
Q84302592	The use of stem cells to repair the injured lung
Q33716668	The various aspects of genetic and epigenetic toxicology: testing methods and clinical applications
Q34186790	Therapeutic opportunities: telomere maintenance in inducible pluripotent stem cells.
Q38035076	Therapeutic revascularisation of ischaemic tissue: the opportunities and challenges for therapy using vascular stem/progenitor cells
Q28275596	Therapeutics from Adult Stem Cells and the Hype Curve
Q27316927	To clone or not to clone? Induced pluripotent stem cells can be generated in bulk culture
Q28083650	Toward beta cell replacement for diabetes
Q28833688	Toward pluripotency by reprogramming: mechanisms and application
Q92771435	Traditional two-dimensional mesenchymal stem cells (MSCs) are better than spheroid MSCs on promoting retinal ganglion cells survival and axon regeneration
Q39241230	Transactivator protein: An alternative for delivery of recombinant proteins for safer reprogramming of induced Pluripotent Stem Cell
Q35754369	Transcriptome Signature and Regulation in Human Somatic Cell Reprogramming
Q54976709	Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS.
Q35617354	Transcriptomic analysis of pluripotent stem cells: insights into health and disease
Q39276115	Transdifferentiation and reprogramming: Overview of the processes, their similarities and differences
Q39642592	Transduction of E13 murine neural precursor cells by non-immunogenic recombinant adeno-associated viruses induces major changes in neuronal phenotype
Q34035837	Transgene excision has no impact on in vivo integration of human iPS derived neural precursors
Q36743366	Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells.
Q34699757	Transient p53 suppression increases reprogramming of human fibroblasts without affecting apoptosis and DNA damage
Q99631269	Translating Embryogenesis to Generate Organoids: Novel Approaches to Personalized Medicine
Q61804246	Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells
Q100503547	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia
Q41169418	Tumorigenic and Differentiation Potentials of Embryonic Stem Cells Depend on TGFβ Family Signaling: Lessons from Teratocarcinoma Cells Stimulated to Differentiate with Retinoic Acid
Q84053616	Tumour microenvironment: the same, but different
Q92168616	Ultra-High-Frequency Reprogramming of Individual Long-Term Hematopoietic Stem Cells Yields Low Somatic Variant Induced Pluripotent Stem Cells
Q37561102	Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy
Q26784399	Understanding the molecular basis of autism in a dish using hiPSCs-derived neurons from ASD patients
Q33720285	Understanding the roadmaps to induced pluripotency.
Q50600342	Unique features of mutations revealed by sequentially reprogrammed induced pluripotent stem cells.
Q38049545	Urine as a source of stem cells.
Q28073204	Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases
Q38782887	Using human pluripotent stem cells to study Friedreich ataxia cardiomyopathy.
Q26799590	Using iPS Cells toward the Understanding of Parkinson's Disease
Q28081565	Utilizing induced pluripotent stem cells (iPSCs) to understand the actions of estrogens in human neurons
Q39349208	Vascular aging: Molecular mechanisms and potential treatments for vascular rejuvenation.
Q38358089	Werner Syndrome-specific induced pluripotent stem cells: recovery of telomere function by reprogramming
Q27004818	Which stem cells to repair the endocrine pancreas?
Q36332809	Whole-exome sequencing of fibroblast and its iPS cell lines derived from a patient diagnosed with xeroderma pigmentosum
Q36605066	Whole-genome mutational burden analysis of three pluripotency induction methods.
Q34250405	Whole-genome sequencing identifies genetic variances in culture-expanded human mesenchymal stem cells
Q33729692	X Chromosome of female cells shows dynamic changes in status during human somatic cell reprogramming
Q38105583	X chromosome inactivation and epigenetic responses to cellular reprogramming
Q35849292	X-chromosome inactivation in rett syndrome human induced pluripotent stem cells
Q59528860	Zelltherapie am Augenhintergrund – gestern, heute, morgen
Q36528994	Zinc-finger nuclease-mediated correction of α-thalassemia in iPS cells
Q42083879	Zscan4 promotes genomic stability during reprogramming and dramatically improves the quality of iPS cells as demonstrated by tetraploid complementation
Q35649160	Zscan4 transiently reactivates early embryonic genes during the generation of induced pluripotent stem cells
Q53109923	[Cellular therapy of diabetes: focus on the latest developments].
Q54593982	[Human pluripotent stem cells: opening key for pathological modeling].
Q51849537	[Induced pluripotent stem cells: youthful indiscretions].
Q83679845	[The genetic safety of induced pluripotent stem (iPS) cells]
Q34756386	iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes
Q84087127	iPS genomes investigated
Q64089132	iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?
Q33919340	iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth
Q33559864	iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types
Q38975316	iPSCs and fibroblast subclones from the same fibroblast population contain comparable levels of sequence variations.
Q47598750	iPSCs, aging and age-related diseases
Q34046315	iPSCs-based anti-aging therapies: Recent discoveries and future challenges.
Q42545969	iPSCs: Unstable origins?
Q39762859	iPSCs: induced back to controversy
Q39173476	mRNA transfection-based, feeder-free, induced pluripotent stem cells derived from adipose tissue of a 50-year-old patient
Q37428226	p53 isoform Δ133p53 promotes efficiency of induced pluripotent stem cells and ensures genomic integrity during reprogramming
Q51079814	Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells.

P6179	Dimensions Publication ID	1053576860
P356	DOI	10.1038/NATURE09805
P3181	OpenCitations bibliographic resource ID	1179495
P932	PMC publication ID	3074107
P698	PubMed publication ID	21368825
P5875	ResearchGate publication ID	50267711

P50	author	George Q. Daley	Q5543595
		Juan Carlos Izpisúa Belmonte	Q6299291
		Alessandra Giorgetti	Q57962276
		Kevin Eggan	Q91046031
		Suneet Agarwal	Q98897236
		Yuin-Han Loh	Q99363763
		Athanasia Panopoulos	Q105545992
		Philip D Manos	Q114405559
		Núria Montserrat	Q41679242
		Derrick Rossi	Q50173077
P2093	author name string	Ewen F Kirkness
		Lawrence S B Goldstein
		James A Thomson
		Kun Zhang
		Zhe Li
		Sergio Ruiz
		Evangelos Kiskinis
		Junying Yu
		Jessica Antosiewicz-Bourget
		Ho-Lim Fung
		Athurva Gore
		Je-Hyuk Lee
		Melissa L Wilbert
		Mason A Israel
		Jessica E Young
		Isabel Canto
P2860	cites work	The diploid genome sequence of an individual human	Q21090194
		Identification and Classification of Chromosomal Aberrations in Human Induced Pluripotent Stem Cells	Q56768636
		Distributions of exons and introns in the human genome	Q80241605
		Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders	Q24558589
		Targeted capture and massively parallel sequencing of 12 human exomes	Q24615381
		A comprehensive catalogue of somatic mutations from a human cancer genome	Q24628532
		A census of human cancer genes	Q24647081
		The Catalogue of Somatic Mutations in Cancer (COSMIC)	Q24653244
		DAVID: Database for Annotation, Visualization, and Integrated Discovery	Q27499374
		Induced pluripotent stem cell lines derived from human somatic cells	Q27860597
		Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors	Q27860937
		Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.	Q28131663
		Multiplex amplification of large sets of human exons	Q28253118
		Immortalization eliminates a roadblock during cellular reprogramming into iPS cells	Q28254388
		Reprogramming of human somatic cells to pluripotency with defined factors	Q28262710
		Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays	Q28263829
		SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation	Q28282761
		Genome remodelling in a basal-like breast cancer metastasis and xenograft	Q28395637
		Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm	Q29547194
		Human induced pluripotent stem cells free of vector and transgene sequences	Q29547624
		A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity	Q29614209
		The Ink4/Arf locus is a barrier for iPS cell reprogramming	Q29614210
		Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes	Q29614341
		Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing	Q29614576
		Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons	Q29616199
		Linking the p53 tumour suppressor pathway to somatic cell reprogramming	Q29616507
		Suppression of induced pluripotent stem cell generation by the p53-p21 pathway	Q29619160
		Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution	Q29619477
		Derivation of Embryonic Stem-Cell Lines from Human Blastocysts	Q29999326
		A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells	Q30884171
		The mutation spectrum revealed by paired genome sequences from a lung cancer patient	Q34117627
		Direct genomic selection.	Q34449685
		Quantification of rare allelic variants from pooled genomic DNA	Q34954811
		Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells	Q35007818
		A functionally characterized test set of human induced pluripotent stem cells	Q35588556
		Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation	Q37089570
		Digital RNA allelotyping reveals tissue-specific and allele-specific gene expression in human	Q37343820
		A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity	Q39618673
		Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming	Q39879443
		Lentivirus-delivered stable gene silencing by RNAi in primary cells	Q41996459
		Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions.	Q51923085
P4510	describes a project that uses	11a	Q54581058
		11b	Q54581062
		17a	Q54582436
		17b	Q54582439
		29a	Q54584269
		29e	Q54584277
		dH1cf16-iPS-1	Q54831049
		CV-hIPS-B	Q54853956
P433	issue	7336
P407	language of work or name	English	Q1860
P921	main subject	cell line	Q21014462
		Human Induced Pluripotent Stem Cells	Q88981775
P304	page(s)	63-67
P577	publication date	2011-03-01
P1433	published in	Nature	Q180445
P1476	title	Somatic coding mutations in human induced pluripotent stem cells
P478	volume	471

Q54581058	11a
Q54581062	11b
Q54582436	17a
Q54582439	17b
Q54584269	29a
Q54584277	29e
Q54853956	CV-hIPS-B
Q93460590	CV-hIPS-F
Q54831049	dH1cf16-iPS-1

Somatic coding mutations in human induced pluripotent stem cells

scientific article (publication date: 3 March 2011)

Reverse relations